Low-dose UVA1 phototherapy for proximal and acral scleroderma in systemic sclerosis.
Previous studies report the benefit of UVA1 phototherapy in treating acrosclerosis in patients with systemic sclerosis. We carried out a retrospective study to examine the effectiveness of UVA1 phototherapy in scleroderma affecting acral and proximal sites in patients with this disease. Patients with systemic sclerosis (diffuse type, n=5; limited type, n=3) underwent low-dose UVA1 radiation (30-40 J/cm(2)) thrice weekly. In all patients skin lesions improved, demonstrated by a fall in the modified Rodnan skin score ranging from 8 to 18 points in diffuse systemic sclerosis and 6 to 10 points in limited disease. This study would suggest that UVA1 phototherapy is effective for scleroderma affecting proximal and acral sites in patients with systemic sclerosis.
Rose
Rebecca F
RF
Department of Dermatology, The General Infirmary at Leeds, Leeds, UK. beckyrose@doctors.org.uk
Turner
David
D
Goodfield
Mark J D
MJ
Goulden
Victoria
V
D000328:Adult; D000368:Aged; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D008875:Middle Aged; D010789:Phototherapy; D012594:Scleroderma, Localized / Q000628:therapy*; D012595:Scleroderma, Systemic / Q000628:therapy*; D016896:Treatment Outcome